source
- Amgen files label update for Tavneos as FDA intensifies withdrawal pushAmgen has submitted a supplemental filing to the FDA to revise the prescribing information for its osteoporosis drug Tavneos. The amendment adds expanded safety warnings as the agency escalates it…
- Johnson & Johnson drops two CAR-T lymphoma programs as market competition intensifiesJohnson & Johnson announced it is discontinuing two CAR-T cell therapy programs aimed at treating B-cell lymphoma. The decision comes as the market for lymphoma treatments has become crowded, with…